Test acetaminophen — Competitive Intelligence Brief

Test acetaminophen (Test acetaminophen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-opioid analgesic. Area: Pain relief.

phase 3 Non-opioid analgesic COX Pain relief Small molecule

Target snapshot

Test acetaminophen (Test acetaminophen) — Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division. Acetaminophen works by inhibiting the production of prostaglandins, which are chemicals that cause pain and fever.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Test acetaminophen TARGET	Test acetaminophen	Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division	phase 3	Non-opioid analgesic	COX
Celebrex	celecoxib	Pfizer Inc. (originally Searle/Pharmacia)	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	COX-2	1998-12-31
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
Diclofenac oral + scopolamina oral	Diclofenac oral + scopolamina oral	Hospital de Clinicas de Porto Alegre	marketed	NSAID + anticholinergic combination	COX-1/COX-2 (diclofenac); muscarinic acetylcholine receptors (scopolamine)
aspirin and/or clopidogrel	aspirin and/or clopidogrel	Asan Medical Center	marketed	Antiplatelet agent	COX (aspirin); P2Y12 receptor (clopidogrel)
Ketorolac + Ranibizumab	Ketorolac + Ranibizumab	Università degli Studi di Brescia	marketed	NSAID + anti-VEGF monoclonal antibody fragment	COX enzymes (ketorolac); VEGF-A (ranibizumab)
Postoperative pain management with metamizole	Postoperative pain management with metamizole	Medical University of Silesia	marketed	Non-selective NSAID (nonsteroidal anti-inflammatory drug)	Cyclooxygenase (COX-1 and COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2036-05-27 — Celebrex · 10722456 · Formulation · US
• 2036-05-27 — Celebrex · 10799517 · Formulation · US
• 2036-05-27 — Celebrex · 9949990 · Formulation · US
• 2036-05-27 — Celebrex · 9795620 · Formulation · US
• 2036-05-27 — Celebrex · 9572819 · Formulation · US
• 2036-05-27 — Celebrex · 10376527 · Formulation · US

Sponsor landscape (Non-opioid analgesic class)

1. Allodynic Therapeutics, Inc · 1 drug in this class
2. GlaxoSmithKline · 1 drug in this class
3. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 1 drug in this class
4. Muhammad Rahman Efendi Nasution · 1 drug in this class
5. Nevakar, Inc. · 1 drug in this class